Our Products

THE COHERUS PIPELINE TARGETS ATTRACTIVE MARKETS

Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status
Long Acting G-CSF Pipeline
Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status
CHS-1701 pegfilgrastim (Neulasta)

Febrile neutropenia

Arrow Right

BLA on track for resubmission at end of 2017 / early Q1 2018

Anti-TNF Pipeline
Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status
CHS-1420 adalimumab (HUMIRA)

Ankylosing Spondylitis

Crohn's disease

Juvenile Idiopathic Arthritis

Psoriasis (PsO)

Psoriatic Arthritis

Rheumatoid Arthritis (RA)

Ulcerative Colitis

Hidradentis suppurativa Uveitis

Arrow Right

Phase 3 clinical studies in Psoriasis completed

Focus on securing competitive launch in US market

CHS-0214 etanercept (Enbrel)

Ankylosing Spondylitis Juvenile

Idiopathic Arthritis Psoriasis (PsO)

Psoriatic Arthritis Rheumatoid

Arthritis (RA)
Arrow Right

Phase 3 clinical studies in Psoriasis and RA completed

Focus on US market(2)

Ophthalmology Pipeline
Candidate Originator Product Originator Approved Indications Pre-Clinical Phase 1 Phase 31 Status
CHS-3351 ranibizumab (LUCENTIS)

Neovascular (Wet) Age-Related Macular Degeneration

Macular Edema Following Retinal Vein Occlusion

Diabetic Macular Edema

Diabetic Retinopathy

Myopic Choroidal Neovascularization

Arrow Right

Pre-clinical development


1 Phase 3 or BLA-enabling study

2 The therapeutic protein in etanercept is subject to certain originator-controlled United States patents expiring in 2028 and 2029. Assuming these patents are valid and enforceable, and that we would be unable to obtain a license to them, we do not expect to commercialize CHS-0214 in the United States prior to their expiration